They started as a treatment for diabetes, but GLP-1 medications like Ozempic and Wegovy have quickly become the most talked-about drugs in modern medicine.
With two-thirds of Australians now living with obesity, the shift from lifestyle-only messaging to pharmaceutical solutions is accelerating, but is it just a new form of diet culture, or a genuine medical breakthrough?
Today, we get rare access to one of the original pioneers of the science. Professor Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk, joins us to answer your questions.
Plus, Lotte addresses the headlines regarding side effects and why the FDA recently removed a major warning from the label.
🗞️ HEADLINES
📩 GET IN TOUCH
Got a story, news tip-off, feedback or dilemma?
Send us a voice note or email us at thequicky@mamamia.com.au
🎙️ CREDITS
Hosts: Taylah Strano & Claire Murphy
Guest: Professor Lotte Bjerre Knudsen, Chief Scientific Advisor at Novo Nordisk
Group Executive Producer: Ilaria Brophy
Audio Producer: Lu Hill
Support independent women's media
Check out The Quicky Instagram here and our TikTok here
Discover more Mamamia podcasts here
Did you know some of our shows are now in video on the Apple Podcast app? Make sure your phone is up to date and check it out here!
Mamamia acknowledges the traditional owners of the land on which we have recorded this podcast.
Become a Mamamia subscriber: https://www.mamamia.com.au/subscribe
See omnystudio.com/listener for privacy information.